Analysis Of Income And Expense [Abstract]

Heidelberg Pharma AG - Filing #6821989

Concept 2020-12-01 to
2021-11-30
2019-12-01 to
2020-11-30
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
1.749.829 EUR
8.487.938 EUR
Material income and expense [abstract]
Research and development expense
18.750.257 EUR
18.286.980 EUR
Finance income (cost)
494 EUR
14 EUR
Revenue and other operating income
2.313.658 EUR
9.575.864 EUR
Operating expense
27.944.722 EUR
27.860.584 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates and joint ventures accounted for using equity method
13 EUR
71 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.